A STUDY ON THE EFFECT OF EXACERBATIONS ON THE QUALITY OF LIFE OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE

  • PUSHPAVALLI KOTHA Department of Pharmacy Practice, Aditya College of Pharmacy, Surampalem, Andhra Pradesh, India
    pushpavallikotha@gmail.com
  • Naga Vamsi Krishna Vasabhakthula Department of Pharmacy Practice, Aditya College of Pharmacy, Surampalem, Andhra Pradesh, India
  • Christine Undurthi Department of Pharmacy Practice, Aditya College of Pharmacy, Surampalem, Andhra Pradesh, India
  • Siva Ganga M Department of Pharmacy Practice, Aditya College of Pharmacy, Surampalem, Andhra Pradesh, India

Abstract

Aim:  The main aim of this study is to evaluate the effect of exacerbations on the quality of life of the patients with chronic obstructive pulmonary disease.


Materials and Methods: Patients of both the genders and with an age of above 18 years of patients who were diagnosed with COPD were included in this prospective study. Modified British Medical Research Council (m-MRC) Dyspnoea Scale was used to establish functional impairment due to shortness of breath in the study participants. Saint George's Respiratory Questionnaire (SGRQ) was also used to assess the patient’s overall health and quality of life-based on self-report.


Results: Among the 110 study participants, 87.3% were males and 12.7% were females. It was observed that majority of the patients were in the age group 51-60 years (43.6%). The most frequently observed co-morbidities were hypertension (22.7%) followed by diabetes mellitus (19.1%). Most of the patients were observed to be with m-MRC grade-3 (42.7%) followed by m-MRC garde-2 (39.1%). The SGRQ score was observed to be increased with increase in the frequency of exacerbations.


Conclusion: Clinical Pharmacist should take the responsibility in providing effective evidence based therapeutic recommendations for the better management and well being of the COPD patients.

Keywords: Chronic Obstructive Pulmonary Disease, Exacerbations, Hypertension

Downloads

Download data is not yet available.

References

1. Frank TL, Gazell ML, Linehan MF, Morris JA, Frank PI. The estimated prevalence of chronic obstructive pulmonary disease in a general practice population. Prim Care Respir J.2007;16:169–173.

2. van der Molen T. Co morbidities of COPD in primary care; frequency, relation to COPD, and treatment consequences. Prim Care Respir J.2010;19:326–334.

3. García- Sagredo P, Morales L, Carmona M. Co-morbidity in patients with chronic obstructive pulmonary disease in family practice: a cross sectional study. BMC FamPract. 2013;14:11.

4. Tashkin D, Miravitlles M, Price D, Metzdorf N, Kupas K, Celli B. Rate of co-morbidities during the 4-year UPLIFT trial in COPD: A post-hoc analysis. Chest. 2014;146:67A.

5. Sarika Pandey, Rajiv Garg, Surya Kant, Priyanka Gaur. Chronic Obstructive Pulmonary Disease with Anaemia as Co-morbidity in North Indian Population. Resp jl.2018,7:152.

6. Fumagalli G, Fabiani F, Forte S, Napolitano M, Balzano G, Bonini M, et al. INDACO project: COPD and link between co morbidities, lung function and inhalation therapy. Multidisciplinary respiratory medicine. 2015;19:4.

7. Dal Negro RW, Tognella S, Tosatto R, Dionisi M, Turco P, Donner CF. Costs of chronic obstructive pulmonary disease in Italy:the SIRIO study (social impact of respiratory integrated outcomes) Respir Med.2008;102(1):92–101.

8. Sievi NA, Senn O, Brack T, Brutsche MH, Frey M, Irani S. Impact of co morbidities on physical activity in COPD. Respirology.2015;20:413–418.

9. Joachim Saur, Martinborggrefe, Frederic Trinkmann .Cardiovascular Co-morbidities in Chronic Obstructive Pulmonary Disease (COPD). Current Considerations for Clinical Practice.Published:10 January 2019; 8(1), 69.

10. Velin Stratev, Diana Patkova. Co-morbidities of COPD in Bulgarian patients-Prevalence and association with severity and inflammation. Chest jl.16 April 2018;16(1),102-109.

11. Camiciottoli G, Bigazzi F, Magni C, Bonti V, Diciotti S, Bartolucci M, Mascalchi M, Pistolesi M: Prevalence of co morbidities according to predominant phenotype and severity of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2016;11: 2229– 2236.

12. Global initiative for chronic obstructive pulmonary disease, 2019. Global obstructive lung disease. NHLBI/ WHO report. NIH publication, NO.2701.

13. Wig K.L, Guleira K.S. “Certain clinical and epidemiological aspects of chronic bronchitis as seen in Northern India”, Indian Journal of Chest Diseases, 1964, 6; 183-94.

14. Altose MD, Assessment and management of breathlessness, Int j res med.1985; 22:88-92.

15. Hana Mullerova. St.George’s Respiratory Questionnaire Score Predicts Outcomes in Patients with COPD: Analysis of Individual Patient data in the COPD Biomarkers Qualification Consortium Database. Journal of COPD foundation, 2017: 4(2); 141-149.
Published
15-12-2020
Statistics
131 Views | 134 Downloads
Citatons
How to Cite
KOTHA, P., N. V. K. Vasabhakthula, C. Undurthi, and S. G. M. “A STUDY ON THE EFFECT OF EXACERBATIONS ON THE QUALITY OF LIFE OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE”. World Journal of Current Medical and Pharmaceutical Research, Dec. 2020, pp. 319–321, doi:10.37022/wjcmpr.vi.161.
Section
Research Articles